Cognition Therapeutics (CGTX) Liabilities and Shareholders Equity (2020 - 2026)

Cognition Therapeutics (CGTX) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $36.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 53.79% year-over-year to $36.1 million; the TTM figure through Mar 2026 stood at $147.5 million (up 27.55% YoY), while the FY2025 annual figure was $48.4 million, up 60.05% from the prior year.
• Liabilities and Shareholders Equity slipped to $36.1 million in Q1 2026 per CGTX's latest filing, from $48.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $58.7 million in Q1 2022 and bottomed at $19.6 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $40.1 million across 5 years, with a median of $38.9 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 300.01% — and 2025, when it plunged 42.91%.
• Cognition Therapeutics' Liabilities and Shareholders Equity stood at $50.4 million in 2022, then slumped by 30.27% to $35.2 million in 2023, then retreated by 14.02% to $30.2 million in 2024, then jumped by 60.05% to $48.4 million in 2025, then retreated by 25.32% to $36.1 million in 2026.
• Business Quant data shows CGTX's Liabilities and Shareholders Equity at $36.1 million in Q1 2026, $48.4 million in Q4 2025, and $43.4 million in Q3 2025.